LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Закрыт

СекторЗдравоохранение

140.29 0.24

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

140.04

Макс.

141.94

Ключевые показатели

By Trading Economics

Доход

394M

635M

Продажи

215M

2.6B

P/E

Средняя по отрасли

12.653

35.733

Прибыль на акцию

3.02

Рентабельность продаж

23.995

Сотрудники

7,605

EBITDA

457M

1B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+20.72% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

29 окт. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

442M

19B

Предыдущая цена открытия

140.05

Предыдущая цена закрытия

140.29

Новостные настроения

By Acuity

31%

69%

92 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Biogen Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 сент. 2025 г., 09:30 UTC

Приобретения, слияния, поглощения

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 сент. 2025 г., 08:20 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

5 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

5 сент. 2025 г., 20:37 UTC

Приобретения, слияния, поглощения

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 сент. 2025 г., 20:37 UTC

Приобретения, слияния, поглощения

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 сент. 2025 г., 20:36 UTC

Приобретения, слияния, поглощения

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 сент. 2025 г., 20:36 UTC

Приобретения, слияния, поглощения

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 сент. 2025 г., 20:33 UTC

Приобретения, слияния, поглощения

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 сент. 2025 г., 20:33 UTC

Приобретения, слияния, поглощения

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 сент. 2025 г., 20:31 UTC

Приобретения, слияния, поглощения

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 сент. 2025 г., 20:20 UTC

Отчет

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 сент. 2025 г., 19:23 UTC

Обсуждения рынка

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 сент. 2025 г., 19:22 UTC

Отчет

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 сент. 2025 г., 19:17 UTC

Обсуждения рынка

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 сент. 2025 г., 18:59 UTC

Отчет

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 сент. 2025 г., 18:35 UTC

Обсуждения рынка

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 сент. 2025 г., 17:25 UTC

Обсуждения рынка

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 сент. 2025 г., 17:20 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 сент. 2025 г., 17:17 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

5 сент. 2025 г., 17:17 UTC

Обсуждения рынка

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 сент. 2025 г., 17:03 UTC

Обсуждения рынка

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 сент. 2025 г., 16:39 UTC

Приобретения, слияния, поглощения

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 сент. 2025 г., 16:39 UTC

Приобретения, слияния, поглощения

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 сент. 2025 г., 16:39 UTC

Приобретения, слияния, поглощения

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 сент. 2025 г., 16:39 UTC

Приобретения, слияния, поглощения

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 сент. 2025 г., 16:37 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Global Equities Roundup: Market Talk

5 сент. 2025 г., 16:37 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Global Energy Roundup: Market Talk

5 сент. 2025 г., 16:37 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 сент. 2025 г., 16:20 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

5 сент. 2025 г., 16:16 UTC

Отчет

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Сравнение c конкурентами

Изменение цены

Biogen Inc Прогноз

Целевая цена

By TipRanks

20.72% рост

Прогноз на 12 месяцев

Средняя 169.81 USD  20.72%

Максимум 260 USD

Минимум 118 USD

Основано на мнении 26 аналитиков Wall Street, спрогнозировавших целевые цены для Biogen Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

26 ratings

12

Покупка

14

Удержание

0

Продажа

Техническая оценка

By Trading Central

118.15 / 121.17Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

92 / 371Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat